Whilst many preclinical studies have been challenging to translate to humans, the safe and well accepted use of the β3AR agonist, Mirabegron, for patients with overactive bladder syndrome makes the opportunity for drug repurposing and translation of our findings immediately feasible. The gene discussed is ADRB3; the disease is Urinary urgency.